Phenotype of Infection-Induced Human Plasmablasts in the Blood
==============================================================

Several studies have analyzed the kinetics and phenotypic changes of B cells in the blood of vaccinated or infected individuals by flow cytometry. Differentiation into plasmablasts (PB) is most commonly monitored with surface markers CD19, CD20, CD27, CD38, and CD138 and intracellular marker Ki-67 (Table [1](#T1){ref-type="table"}). CD38 catalyzes the formation of cyclic ADP--ribose and NADP and regulates Ca^+^ signals in lymphoid cell (Partida-Sanchez et al., [@B31]). CD27, a member of the TNF receptor family that induces differentiation and promotes survival (Borst et al., [@B7]), is expressed on the majority of memory B cells (Wu et al., [@B41]) and is highly up-regulated on plasmablasts (Qian et al., [@B35]). CD20 is down-regulated when blood-derived memory B cells differentiate into plasmablasts (Jego et al., [@B17]). Plasmablasts proliferate extensively, evident by the intracellular expression of proliferation-associated protein Ki-67 (its function is unclear; Wrammert et al., [@B40]; Qian et al., [@B35]). When human PBMC are differentiated *in vitro* with IL-6, syndecan-1 (CD138) is acquired as a marker of plasma cells (PC; Jego et al., [@B17]). This is similar in mouse studies where CD138 is generally used as a PC marker (MacLennan et al., [@B23]). However, the distinction between PB and PCs in human blood based on CD138 is not obvious. CD138^+^ plasmablasts proliferate and express CD27 and CD38 at similar levels to CD138^−^ plasmablasts. Interestingly, both plasmablast subsets are induced similarly after vaccination with tetanus-, hepatitis A/B-, or influenza-vaccine (Qian et al., [@B35]). The CD27^high^CD19^low^ PB population in peripheral blood contains subsets with high or low expression of cell proliferation-associated proteins (Yoshida et al., [@B42]), and CD138^+^ cells might represent re-circulating secondary lymphoid organs-derived PCs, or PB in an end-differentiation stage destined to become secondary lymphoid organ-resident PCs. Because of the diffuse transition from the CD138^−^ to the CD138^+^ phenotype most studies do not differentiate between the two populations of cells and use the term antibody-secreting cells (ASC; Wrammert et al., [@B40], [@B39]; He et al., [@B15]; Lee et al., [@B21]). The term acute plasmablasts will be used here to associate the CD19^low^CD20^−^CD27^high^CD38^high^CD138^+/−^ cells appearing after infection with the acute phase of the immune response and to differentiate them from steady-state plasmablasts (Mei et al., [@B25]), although any potential functional or phenotypical differences have not been studied so far.

###### 

**Markers of infection-induced plasmablasts and plasma cells in human blood**.

  Marker   Function                                                                           Memory B cells   Plasmablasts   Plasma cells   Reference
  -------- ---------------------------------------------------------------------------------- ---------------- -------------- -------------- -------------------------------------------------------------------------
  CD19     Transmembrane signaling molecule; part of BCR complex; regulating BCR signal       \+               Low            Low            Engel et al. ([@B10]), Mei et al. ([@B24]), Jacobi et al. ([@B16])
  CD20     Transmembrane signaling molecule; part of the BCR complex                          \+               −              −              Arpin et al. ([@B1]), Jacobi et al. ([@B16]), Kuijpers et al. ([@B18])
  CD27     TNF receptor family                                                                \+               ++             +++            Borst et al. ([@B7]), Mei et al. ([@B24]), Jacobi et al. ([@B16])
  CD38     Signaling molecule and enzyme that catalyzes the formation of cyclic ADP--ribose   +/−              ++             +++            Partida-Sanchez et al. ([@B31]), Mei et al. ([@B24])
  CD138    Heparan sulfate proteoglycan; syndecan-1                                           −                +/−            \+             Qian et al. ([@B35])
  Ki-67    Protein expressed intracellularly during cell division                             −                \+             +/−            Wrammert et al. ([@B40]), Qian et al. ([@B35]), Yoshida et al. ([@B42])

Timing of Plasmablast Appearance in the Blood
=============================================

The timing of acute PB appearance in the blood is strikingly consistent after immunization or infection: Flow cytometry analysis or ELISPOT performed *ex vivo* with human PBMCs sampled daily after vaccination with attenuated yellow fever strain YF-17D (Querec et al., [@B36]), inactivated influenza vaccine (Cox et al., [@B9]; Moldoveanu et al., [@B26]; Wrammert et al., [@B40]; Halliley et al., [@B14]; He et al., [@B15]), tetanus vaccine (Odendahl et al., [@B29]; Qian et al., [@B35]), and after infection with Respiratory Syncytial Virus (Lee et al., [@B21]) or dengue virus (Balakrishnan et al., [@B3]; Wrammert et al., [@B39]) showed that plasmablast numbers peak consistently at day 6 or 7. The response thus seems to be independent of the adjuvant used and independent of the route of immunization. The appearance of PB in the blood is transient after vaccination (Odendahl et al., [@B29]; Lee et al., [@B21]) whereas the duration of the response depends on the persistence of the virus after natural infection. After infection with acute viruses such as influenza or dengue the PB numbers drop to baseline level within 2--3 weeks after the onset of disease (Balakrishnan et al., [@B3]; Wrammert et al., [@B39]). Data from RSV-infected patients suggest that circulating PBs are produced as long as the virus is actively shed from infected cells (Lee et al., [@B20]). In contrast to the predictable time of appearance, mechanisms that determine the magnitude of the response seem to be more difficult to define: Data from vaccinees and from patients with natural viral infections show a huge variability in acute PB numbers between individuals, suggesting that the plasmablast response is governed by multiple factors.

The impact and requirement of T cell help is unclear. The acute PB responses observed after natural viral infection may differ in magnitude between primary and secondary infections, but the time of PB appearance in the circulation is similar, suggesting that pre-existing T cell help may not be required (Wrammert et al., [@B40]; Querec et al., [@B36]; Balakrishnan et al., [@B3]). However, it is difficult to exclude pre-existing immunity to viruses in endemic areas with absolute certainty, and therefore the comparison of primary versus secondary response is complex in the context of natural infections. In a controlled vaccination scenario, Blanchard-Rohner et al. ([@B6]) demonstrate that the ASC response in naïve individuals peaks at day 10 after primary vaccination with inactivated rabies vaccine, whereas an accelerated response with a peak at day 7 is observed after booster vaccinations. Studies in mice show that specific T cell help promotes germinal center formation after viral infection, whereas absence of specific T cell help results in an increased extrafollicular response (Fink et al., [@B11]). PB formation *in vitro* is T-cell independent (Lane et al., [@B19]) and T cells can suppress the differentiation of memory B cell differentiation into PB in a CD40L-dependent manner (Arpin et al., [@B2]; Callard et al., [@B8]). Possibly the timing and T cell dependence of acute PB responses depends on the nature of the antigen and the engagement of pattern recognition receptors. In *in vitro* systems, TLR7 and 9 ligands are able to facilitate memory activation directly via TLR9 signaling in human memory B cells (Good et al., [@B13]) or indirectly via TLR7-mediated activation of dendritic cells in mice (Pordes et al., [@B33]) and via pDC-derived IFN-I in humans (Bekeredjian-Ding et al., [@B4]). It is thus possible that activation of memory B cells by viral infection is different from activation of memory B cells by recombinant vaccines. More studies in humans are required though to elucidate the mechanisms involved in T cell-dependent and -independent activation of acute PBs.

Origin of Acute-Phase Plasmablasts
==================================

A recent study with HIV-infected persons on anti-retroviral treatment who were vaccinated with H1N1 vaccine and could be grouped into a responder and a non-responder group showed that the PB response at day 7 was predictive for the establishment of memory and for specific antibody titers at day 28. The study further showed that induction of PB and memory populations correlated with the capacity of B cells to upregulate IL-21 receptor, which differed in the responder- and non-responder group (Pallikkuth et al., [@B30]). In a Systems Biology approach Querec et al. ([@B36]) found that TNFRSF17 expression in PBMCs collected at day 7 after yellow fever vaccination had the most predictive value for neutralizing antibody titers at day 28. Given the high expression of TNFRSF17 on PBs (Good et al., [@B13]) one could conclude that the magnitude of the PB response at day 7 is predictive for antibody titers at day 28. Given these lines of evidence that the early PB response may be predictive for later immunity, it is crucial to understand the origin(s) of plasmablasts in the context if a given antigen and adjuvant in order to specifically generate B cell subsets which can be triggered during repeated infection. Early *in vitro* experiments with human naïve and memory B cells from tonsils demonstrated that memory B cells differentiate faster and more efficiently into plasmablasts than naïve B cells after unspecific activation with CD40L and in the presence of IL-2 and IL-10 (Arpin et al., [@B1]). More recent studies using Ig sequencing of single plasma blasts and memory B cells to analyze their relation in the context of tetanus vaccination indicated that a given memory B cell precursor can give rise to plasma blasts and memory cells at the same time (Frolich et al., [@B12]). Other studies employing single cell PCR to analyze human cells after influenza infection showed that plasmablasts are more highly mutated than memory cells (Wrammert et al., [@B40], [@B38]), suggesting that PB derive from memory cells that have undergone extensive selection and have possibly reached a threshold affinity required for their activation (O'Connor et al., [@B28]; Phan et al., [@B32]). Furthermore, steady-state PBs in the human gut are affinity matured and selected toward poly-reactivity and specificity for commensal bacteria (Benckert et al., [@B5]). All these data indicate that PBs circulating in the blood at day 6--7 after infection or immunization (acute PBs) are memory B cell-derived. The similar timing of the appearance of acute PBs after primary and booster immunization at least in the context of viral infections suggests that memory B cells can be the source of such PBs in both scenarios (Figure [1](#F1){ref-type="fig"}).

![**Origin of plasmablasts in steady state and during 1^ry^ and 2^ry^ infections in humans**. During steady state, i.e., in healthy individuals the majority of plasmablasts in the circulation is IgA^+^ and is derived from mucosal immune responses (Mei et al., [@B25]). During systemic infection more IgG^+^ cells from non-mucosal secondary lymphoid organs participate in the response. During repeated (2^ry^) systemic infection with the same antigen a majority of the acute-phase plasmablasts are IgG^+^ and derive from memory B cells, which have undergone class-switch and affinity maturation in germinal centers.](fimmu-03-00078-g001){#F1}

However, it needs to be shown which memory B cell subsets are involved and to which extent naïve B cells participate in the acute PB response. Influenza vaccine Fluzone, which is administered via the intradermal route, induces both IgA- and IgG-class-switched PB responses, while numbers of IgA-expressing cells are 10 times lower than the ones of IgG-expressing cells (Sasaki et al., [@B37]). Natural dengue infection induces specific IgA, IgG, and IgM PB (Wrammert et al., [@B39]). Our own studies show a consistent prevalence of IgA-producing cells (mean 65%) in the acute PB population in the blood compared to only 2% IgA cells in the memory B cell pool in a cohort of patients with febrile illness caused by viral infections (unpublished data). Thus, a large part of the plasmablasts circulating during acute infection possibly derive from mucosal sites, similarly as in steady state (Mei et al., [@B25]). What is observed during infection could thus be an amplification of the steady state, with the difference that IgG-class-switched cells become a significant part of the response (Sasaki et al., [@B37]) possibly because more non-mucosal lymphoid organs (lymph nodes) participate in the response. During re-infection (2^ry^ response) the plasmablast response is dominated by IgG^+^ PBs because of the formation of germinal centers in both non-mucosal and mucosal tissues and the generation of IgG-switched memory B cells between 1^ry^ and 2^ry^ infection (Figure [1](#F1){ref-type="fig"}).

Predictive Value of Plasmablast Responses for Immune Memory
===========================================================

Recent systemic approaches to study immune responses after vaccinations in order to find parameters that are predictive of the long-term response have identified dominating plasma blast signatures in acute-phase (day 7) PBMC arrays (Querec et al., [@B36]; Nakaya et al., [@B27]). Natural viral infections can generate very impressive numbers of plasmablasts in the blood, as in the case of dengue virus infection (Balakrishnan et al., [@B3]; Wrammert et al., [@B39]). The important question remains what this means for protection and immune memory induction. Even though there might be some predictive value of the acute response for later protection (Querec et al., [@B36]) there are unsolved questions that need to be addressed. In the context of viral infections it is critical to analyze the antibody response beyond day 28 and to measure protective antibody titers by functional assays and B cell memory by ELISPOT. It is not known whether memory B cells can still provide protection once antibody titers fall below a protective threshold. Memory B cells might be particularly important when neutralizing antibody titers are insufficient to provide sterile protection. Rapid activation of memory B cells and their differentiation into antibody-secreting PBs might provide antibodies in quantities that can at least partially neutralize the virus and stop further dissemination in the organism. Indeed, the 6- to 7-day lag phase between memory B cell activation and plasma blast formation might be important to generate a minimal number of infected cells to trigger an effective T cell response, which will in turn help to boost and maintain B cell memory.

It is still unclear whether only a subset of B cells is triggered during an acute response or whether different B cell subsets differ in their capacity to participate in the acute PB response. Moreover, in the context of long-lasting antibody titers in the blood and the maintenance of memory B cells, it is not known whether siblings of acute, short-lived PBs can become long-lived PCs. A recent study in mice showed that memory B cell-derived antibodies could neutralize an escape variant of West Nile virus whereas bone marrow-derived PCs could only neutralize the original virus (Purtha et al., [@B34]). Moreover, human HIV-specific memory B cells were recently shown to derive from polyclonal memory B cells (Liao et al., [@B22]). It seems thus likely that not only naïve B cells, but also memory B cells are engaged in primary responses or in responses against virus variants. The potential capacity of relatively unspecific memory B cells to further affinity-mature and adapt may thus be important for vaccinations, particularly in adults, since highly affinity matured B cells can efficiently differentiate into plasmablasts. More studies on the re-engagement of memory B cells during persistent viral infections or during re-infection with acute virus variants are required to understand the relevance and potential impact of this type of immune response, and to assess its predictive value for immune memory.
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